Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1982 1
1983 3
1984 2
1986 3
1987 1
1988 1
1989 3
1990 6
1991 6
1992 8
1993 5
1994 5
1995 7
1996 13
1997 21
1998 17
1999 14
2000 25
2001 41
2002 41
2003 41
2004 49
2005 50
2006 56
2007 59
2008 44
2009 61
2010 54
2011 54
2012 53
2013 65
2014 68
2015 79
2016 66
2017 78
2018 89
2019 84
2020 88
2021 91
2022 95
2023 98
2024 88
2025 42

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,621 results

Results by year

Filters applied: . Clear all
Page 1
2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, Caplan L, Gore S, Grossman J, Hansen KE, Lane NE, Ma NS, Magrey M, McAlindon T, Robinson AB, Saha S, Womack C, Abdulhadi B, Charles JF, Cheah JTL, Chou S, Goyal I, Haseltine K, Jackson L, Mirza R, Moledina I, Punni E, Rinden T, Turgunbaev M, Wysham K, Turner AS, Uhl S. Humphrey MB, et al. Arthritis Rheumatol. 2023 Dec;75(12):2088-2102. doi: 10.1002/art.42646. Epub 2023 Oct 16. Arthritis Rheumatol. 2023. PMID: 37845798 Free article. Review.
OBJECTIVE: The objective is to update recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic conditions receiving >3 months treatment with glucocorticoids (GCs) 2.5 mg daily. . …
OBJECTIVE: The objective is to update recommendations for prevention and treatment of glucocorticoid-induced osteoporosis …
Pathogenic mechanisms of glucocorticoid-induced osteoporosis.
Chen M, Fu W, Xu H, Liu CJ. Chen M, et al. Cytokine Growth Factor Rev. 2023 Apr;70:54-66. doi: 10.1016/j.cytogfr.2023.03.002. Epub 2023 Mar 5. Cytokine Growth Factor Rev. 2023. PMID: 36906448 Free PMC article. Review.
However, high doses and long-term use of GCs lead to multiple adverse effects, particularly glucocorticoid-induced osteoporosis (GIO). Excessive GCs exert detrimental effects on bone cells, including osteoblasts, osteoclasts, and osteocytes, leading to impair …
However, high doses and long-term use of GCs lead to multiple adverse effects, particularly glucocorticoid-induced osteopor …
Glucocorticoid induced osteoporosis.
Hu K, Adachi JD. Hu K, et al. Expert Rev Endocrinol Metab. 2019 Jul;14(4):259-266. doi: 10.1080/17446651.2019.1617131. Epub 2019 May 16. Expert Rev Endocrinol Metab. 2019. PMID: 31094232 Review.
INTRODUCTION: Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis. Despite this, many patients receiving glucocorticoids are not evaluated for their skeletal health. ...Pharmacologic prevention and treatment for os …
INTRODUCTION: Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis. Despite th …
Glucocorticoid-induced osteoporosis: an update.
Compston J. Compston J. Endocrine. 2018 Jul;61(1):7-16. doi: 10.1007/s12020-018-1588-2. Epub 2018 Apr 24. Endocrine. 2018. PMID: 29691807 Free PMC article. Review.
Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis and the resulting fractures cause significant morbidity. ...However, teriparatide has been shown to be superior in its effects on BMD and vertebral fracture risk in …
Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis and the resulting fractur …
Glucocorticoid-induced osteoporosis update.
Adami G, Saag KG. Adami G, et al. Curr Opin Rheumatol. 2019 Jul;31(4):388-393. doi: 10.1097/BOR.0000000000000608. Curr Opin Rheumatol. 2019. PMID: 31045947 Review.
PURPOSE OF REVIEW: Steroid-induced osteoporosis or glucocorticoid-induced osteoporosis (GIOP) is a common form of secondary osteoporosis and is a cause of increased morbidity and mortality. ...
PURPOSE OF REVIEW: Steroid-induced osteoporosis or glucocorticoid-induced osteoporosis (GIOP) is a common form o …
Glucocorticoid- and Transplantation-Induced Osteoporosis.
Zavatta G, Clarke BL. Zavatta G, et al. Endocrinol Metab Clin North Am. 2021 Jun;50(2):251-273. doi: 10.1016/j.ecl.2021.03.002. Endocrinol Metab Clin North Am. 2021. PMID: 34023042 Review.
Glucocorticoid-induced osteoporosis is the most common cause of secondary osteoporosis; nonetheless, it remains an undertreated condition. Transplantation-induced osteoporosis encompasses a broad range of unique pathogenetic features with distin …
Glucocorticoid-induced osteoporosis is the most common cause of secondary osteoporosis; nonetheless, it remains …
Glucocorticoid-induced Osteoporosis.
Whittier X, Saag KG. Whittier X, et al. Rheum Dis Clin North Am. 2016 Feb;42(1):177-89, x. doi: 10.1016/j.rdc.2015.08.005. Epub 2015 Oct 24. Rheum Dis Clin North Am. 2016. PMID: 26611558 Review.
Glucocorticoid-induced osteoporosis (GIOP) is one of the most common and serious adverse effects associated with glucocorticoid use. ...
Glucocorticoid-induced osteoporosis (GIOP) is one of the most common and serious adverse effects associated with glucoc …
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.
Chotiyarnwong P, McCloskey EV. Chotiyarnwong P, et al. Nat Rev Endocrinol. 2020 Aug;16(8):437-447. doi: 10.1038/s41574-020-0341-0. Epub 2020 Apr 14. Nat Rev Endocrinol. 2020. PMID: 32286516 Review.
High doses and long-term use of glucocorticoids lead to an important and common iatrogenic complication, glucocorticoid-induced osteoporosis, in a substantial proportion of patients. Glucocorticoids mainly increase bone resorption during the initial phase (th …
High doses and long-term use of glucocorticoids lead to an important and common iatrogenic complication, glucocorticoid-induced …
Glucocorticoid-induced osteoporosis: 2019 concise clinical review.
Adami G, Saag KG. Adami G, et al. Osteoporos Int. 2019 Jun;30(6):1145-1156. doi: 10.1007/s00198-019-04906-x. Epub 2019 Feb 25. Osteoporos Int. 2019. PMID: 30805679 Review.
Glucocorticoids remain widely used for many medical conditions, and fractures are the most serious common adverse event related to long-term glucocorticoid use. Glucocorticoid-induced osteoporosis (GIOP) develops in a time- and dose-dependent manner, but even …
Glucocorticoids remain widely used for many medical conditions, and fractures are the most serious common adverse event related to long-term …
Glucocorticoid-induced osteoporosis in premenopausal women: management for the rheumatologist.
Chakrabarti K, McCune WJ. Chakrabarti K, et al. Curr Opin Rheumatol. 2023 May 1;35(3):161-169. doi: 10.1097/BOR.0000000000000934. Epub 2023 Mar 20. Curr Opin Rheumatol. 2023. PMID: 36943706 Review.
PURPOSE OF REVIEW: This review seeks to summarize the literature relevant to the treatment of glucocorticoid-induced osteoporosis in premenopausal women; an issue commonly encountered by rheumatologists and yet lacking good clinical practice guidelines. ...Da …
PURPOSE OF REVIEW: This review seeks to summarize the literature relevant to the treatment of glucocorticoid-induced osteop …
1,621 results